Cargando…
NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585731/ https://www.ncbi.nlm.nih.gov/pubmed/34785883 http://dx.doi.org/10.1007/s40274-021-08193-6 |
_version_ | 1784597742421540864 |
---|---|
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-8585731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-85857312021-11-12 NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19 PharmacoEcon Outcomes News News Item Springer International Publishing 2021-11-13 2021 /pmc/articles/PMC8585731/ /pubmed/34785883 http://dx.doi.org/10.1007/s40274-021-08193-6 Text en © Springer International Publishing AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | News Item NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19 |
title | NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19 |
title_full | NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19 |
title_fullStr | NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19 |
title_full_unstemmed | NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19 |
title_short | NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19 |
title_sort | nz's pharmac to fund baricitinib for moderate-to-severe covid-19 |
topic | News Item |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585731/ https://www.ncbi.nlm.nih.gov/pubmed/34785883 http://dx.doi.org/10.1007/s40274-021-08193-6 |